DSM-Firmenich inaugurates a new Jakarta office and expands its Karawang manufacturing site to enhance regional production and innovation capabilities. The initiative supports sustainability trends in the flavors and nutrition sectors, utilizing green energy to cut significant carbon emissions alongside capacity growth. Localizing production optimizes supply chains for the Indonesian market, balancing operational efficiency with corporate decarbonization commitments.
11 articles
DSM-Firmenich opened a new Jakarta office and expanded its Karawang manufacturing facility in Indonesia to boost production capacity and local innovation for flavors, fragrances, and nutrition. The pr
DSM-Firmenich initiated patent infringement litigation in China against multiple entities regarding unauthorized sclareol production. The company seeks court orders to cease infringement and secure co
DSM-Firmenich reported a 6% drop in Q1 adjusted EBITDA and 3% sales decline due to currency effects, yet maintained full-year guidance citing robust underlying volumes in perfumery and beauty segments
DSM-Firmenich reported Q1 core profit matching forecasts, with adjusted EBITDA reaching €434 million. Strong demand for perfumery and beauty products drove the results.
DSM-Firmenich China President Zhou Tao outlines the company's "15th Five-Year Plan" strategy, highlighting new investments in fermentation and fragrance facilities to meet growing demand in nutrition
DSM-Firmenich forecasts higher margins and organic growth for 2026, factoring in current economic challenges while assuming no prolonged impact from the Middle East conflict.
DSM-Firmenich reported a decline in Q4 sales driven by negative currency impacts despite organic growth, with a full-year outlook scheduled for release in March 2026.
CVC Capital Partners agreed to purchase DSM-Firmenich's animal nutrition and health business for €2.2 billion, finalizing the company's shift toward consumer-facing nutrition, health, and beauty opera
DSM-Firmenich and Korea’s ASTech have forged a partnership to advance the global UV filters market by establishing a stable supply chain for UV filter ingredients.
DSM-Firmenich completed its €1.08 billion share buyback for capital reduction, cutting issued shares by 4.5% in Q1 2026.
DSM-Firmenich missed Q3 estimates and trimmed guidance due to currency effects, reporting a 5% YoY revenue decline despite 2% organic growth supported by self-help programs.
ChemBrief